.jpg)
1 hour ago
2
Article content
- Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.
- License and collaboration agreement strengthen Boehringer’s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.
- Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Ingelheim, Germany, and Shanghai, China, 26, January 2026 – Boehringer Ingelheim and Simcere Pharmaceutical Group Ltd. (“Simcere”) (HKEX: 2096), today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).
Article content
Article content
Article content
Globally, it is estimated that more than three million people are affected by IBD, a lifelong, progressive condition leading to frequent hospitalization and surgeries, significantly impacting patients’ quality of life. Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this partnership, Boehringer and Simcere aim to advance an innovative approach to potentially redefine treatment possibilities and improve outcomes for patients worldwide.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
SIM0709 is a long-acting humanized bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. It simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that drive the onset and progression of IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.
Article content
Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim said, “In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies. We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life changing option for patients living with IBD.”
Article content
Article content
“Simcere’s bispecific antibody SIM0709 was engineered with our proprietary multi-specific antibody platform with first-in-class potential for IBD treatment. Partnering with Boehringer Ingelheim, with its long‑term commitment and deep expertise in immunology, positions the compound for rigorous global development,” said Gaobo Zhou, Chief Investment Officer, Simcere Pharmaceutical Group. “Together we aim to accelerate the clinical development and advance a treatment option that could improve outcomes for patients world-wide affected by IBD.”
Article content
Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, regulatory and sales milestones up to EUR 1,058 million, as well as royalties on net sales outside of the Greater China territory.
Article content
Boehringer Ingelheim
Article content
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
English (US)